Trends and influences on use of antidiabetic drugs in England, 1992-2003

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 11, 2005, Pages 769-773

  Walley, Tom ^a   Hughes, Dyfrig ^b   Kendall, Helen ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b BANGOR UNIVERSITY   (United Kingdom)

^c Prescription Pricing Authority   (United Kingdom)

Author keywords

Diabetes mellitus; England; Insulins; Oral hypoglycaemic drugs; Prescribing; Trends

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANTIDIABETIC AGENT; BIPHASIC INSULIN; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ARTICLE; DIABETES CONTROL; DRUG USE; FEMALE; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; UNITED KINGDOM;

DIABETES MELLITUS; DRUG UTILIZATION REVIEW; ENGLAND; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PREVALENCE;

EID: 28044450154     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1089     Document Type: Article

References (19)

1. The Diabetes Control and Complications Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. NEJM 1993; 329: 977-986.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. UK Prospective Diabetes Study Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998; 21: 87-92.
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
5. Dept of Health. National service framework for diabetes: Standards. London, 2001.
6. Anon. Management of type 2 diabetes: management of blood glucose. National Institute of Clinical Excellence: London, September 2002.
7. Stalhammar J, Berne C, Svarsudd K. Do guidelines matter? A population based study of diabetes drug use during 20 years. Scan J Prim Health Care 2001; 19: 163-169.
8. Anon. http://www.statistics.gov.uk/statbase/explorer.asp?CTG=3 Accessed 20th August 2004.
9. Anon. Key Health Statistics from General Practice 1998 (Series MB6 No.2). Office of National Statistics: London, 2000.
10. Marsh LC, Cormier DR. Spline Regression Models. Sage Publications: Thousand Oaks, California, 2002.
11. Anon. Rosiglitazone for type 2 diabetes - full guidance no. 9. National Institute for Clinical Excellence: London, August 2000.
12. Anon. Pioglitazone for type 2 diabetes - full guidance no. 21. National Institute for Clinical Excellence: London, March 2001.
13. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycaemic control over 3 years (UKPDS 44). Diabetes Care 1999; 22: 960-964.
14. Technology Evaluation Centre. Special report: the publication of new evidence and effect on physician prescribing behaviour. Assessment Programme 2004; 19(11): 1-17 http://www.bcbs.com/tec/vol19/19_11.html. [Accessed 18 December 2004].
15. Sheldon T, Cullum N, Dawson D, et al. What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews. Br Med J 2004; 329: 999-1003.
16. Hollowell J. The general practice research database: quality of morbidity data. Popul Trends 1997; 87: 36-40.
17. Fleming DM, Schellevis FG, van Casteren V. The prevalence of known diabetes in eight European countries. Eur J Public Health 2004; 14: 10-14.
18. Amos A, McCarty D, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetes Med 1997; 14: S7-S85.
19. Donker G, Fleming D, Schellevis F, Spreeuwenberg P. Differences in treatment regimes, consultation frequency and referral patterns of diabetes mellitus in general practice in five European countries. Fam Pract 2004; 21: 364-369.